Bibliography: library/10665-385385

The reference for library/10665-385385 (who-iris) and any references extracted from it. library · All references.

Export these 121 references: BibTeX · CSL-JSON · RIS · Dublin Core XML · Dublin Core / BIBO JSON-LD

✍ + Add reference (standalone node)

Build a standalone folio-reference/v1 node at references/reference.jsonld from fields or pasted BibTeX / CSL-JSON.



· ✍ Create standalone node on GitHub · Download .jsonld · Download .csl.json ·

121 shown

  1. World Health Organization (2026). Global hepatitis report 2026. World Health Organization.
    10665-385385 · catalogue · link · repository record · ISBN 9789240122383 (electronic version) · source: catalogue/records/10665-385385.dc.json · held: library/10665-385385
    export: BibTeX · RIS · CSL-JSON · DC XML
  2. Resolution WHA63.18. Viral hepatitis. In: Sixty-third World Health Assembly, Geneva, 17–21 May 2010. Resolutions and decisions, annexes. Geneva: World Health Organization; 2010 (http://apps.who.int/gb/ebwha/pdf_files/WHA63-REC1/WHA63_REC1-en.pdf). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.1.json
  3. Resolution WHA67.6. Hepatitis. In: Sixty-seventh World Health Assembly, Geneva, 19–24 May 2014. Resolutions and decisions, annexes. Geneva: World Health Organization; 2014 (http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R6-en.pdf). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.2.json
  4. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022–2030. Geneva: World Health Organization; 2022:2022 (https://iris.who.int/handle/10665/360348).
    · extracted · link · source: references/10665-385385.sec-007.3.json
  5. Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. Geneva, Switzerland: World Health Organization; 2016 (https://iris.who.int/handle/10665/246177). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.4.json
  6. Zhuang H. Functional cure of chronic hepatitis B is not a dream. Journal of Clinical Hepatology. 2025;41(1):2 (https://doi.org/10.12449/jch250101).
    · extracted · doi:10.12449/jch250101 · source: references/10665-385385.sec-007.5.json
  7. Costa GL, Sautto GA. Towards an HCV vaccine: an overview of the immunization strategies for eliciting an effective B-cell response. Expert Rev Vaccines. 2025;24(1):96-120 (https://doi.org/10.1080/14760584.2025.2452955).
    · extracted · doi:10.1080/14760584.2025.2452955 · source: references/10665-385385.sec-007.6.json
  8. WHO R&D Blueprint for Epidemics [website]. World Health Organization; 2024 (https://www.who.int/teams/blueprint/who-r-and-d-blueprint-for-epidemics). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.7.json
  9. Global Reporting System for Hepatitis (GRSH): Project Description. Geneva: World Health Organization; 2016 (https://who-dev5.prgsdev.com/m/teams/global-hiv-hepatitis-and-stis-programmes/hepatitis/strategic-information/global-reporting-system). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.8.json
  10. Global hepatitis report 2017. Geneva: World Health Organization; 2017 (https://iris.who.int/handle/10665/255016). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.9.json
  11. Progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016–2021: actions for impact. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/341412). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.10.json
  12. Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva: World Health Organization; 2024 (https://iris.who.int/handle/10665/376461). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.11.json
  13. The Global Health Observatory (hepatitis) [website]. World Health Organization; 2025 (https://www.who.int/data/gho/data/themes/chronic-viral-hepatitis).
    · extracted · link · source: references/10665-385385.sec-007.12.json
  14. Viral hepatitis country profiles [website]. World Health Organization; 2025 (https://data.who.int/dashboards/hepatitis/epidemiology).
    · extracted · link · source: references/10665-385385.sec-007.13.json
  15. Hepatitis E background paper: SAGE March 2024. Geneva: World Health Organization; 2024 (https://cdn.who.int/media/docs/default-source/immunization/sage/2024/march/hepatitis_e_background_paper_sage_mar24.pdf?sfvrsn=e14438c4_1). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.14.json
  16. World Health Assembly, 45 (1992). Forty-fifth World Health Assembly, Geneva, 4-14 May 1992: resolutions and decisions, annexes. Geneva: World Health Organization; 1992 (https://iris.who.int/handle/10665/175630).
    · extracted · link · source: references/10665-385385.sec-007.15.json
  17. World Health Assembly, 28 (1975). Twenty-eighth World Health Assembly, Geneva, 13-30 May 1975: part I: resolutions and decisions: annexes. Geneva: World Health Organization; 1975 (https://iris.who.int/handle/10665/86022).
    · extracted · link · source: references/10665-385385.sec-007.16.json
  18. Prevention and control of viral hepatitis infection: framework for global action. Geneva: World Health Organization; 2012 (https://iris.who.int/handle/10665/130012). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.17.json
  19. Sustainable Development Goals-SDG Target 3.3 Communicable diseases [website]. United Nations; (https://sdgs.un.org/goals/goal3#targets_and_indicators).
    · extracted · link · source: references/10665-385385.sec-007.18.json
  20. Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016;16(12):1399-408 (https://doi.org/10.1016/S1473-3099(16)30204-3).
    · extracted · doi:10.1016/S1473-3099(16)30204-3 · source: references/10665-385385.sec-007.19.json
  21. Combating hepatitis B and C to reach elimination by 2030: advocacy brief. Geneva, Switzerland: World Health Organization; 2016 ( https://iris.who.int/handle/10665/206453).
    · extracted · link · source: references/10665-385385.sec-007.20.json
  22. World Health Assembly, 75 (2022). Seventy-fifth World Health Assembly: Geneva, 22-28 May 2022: summary records of committees, reports of committees. Geneva: World Health Organization; 2022 (https://iris.who.int/handle/10665/365611). Licence: CC BY-NC-SA 3.0 IGO. 72 | Global hepatitis report 2026
    · extracted · link · source: references/10665-385385.sec-007.21.json
  23. Guidance for country validation of viral hepatitis elimination and path to elimination: technical report. Geneva: World Health Organization; 2023 (https://iris.who.int/handle/10665/373186). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.22.json
  24. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization; 2015 (https://iris.who.int/handle/10665/154590). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.23.json
  25. Preventing perinatal hepatitis B virus transmission: a guide for introducing and strengthening hepatitis B birth dose vaccination. Geneva: World Health Organization; 2015 (https://iris.who.int/handle/10665/208278 ). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.24.json
  26. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection, Updated version, April 2016. Geneva: World Health Organization; 2016 (https://iris.who.int/handle/10665/205035). Licence: CC
    · extracted · link · source: references/10665-385385.sec-007.25.json
  27. World Health Organization. Hepatitis B vaccines: WHO position paper, July 2017 – recommendations. Vaccine. 2019;37(2):223–5 (https://doi.org/10.1016/j.vaccine.2017.07.046).
    · extracted · doi:10.1016/j.vaccine.2017.07.046 · source: references/10665-385385.sec-007.26.json
  28. Monitoring and evaluation for viral hepatitis B and C: recommended indicators and framework. Geneva: World Health Organization; 2016 (https://iris.who.int/handle/10665/204790). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.27.json
  29. WHO guidelines on hepatitis B and C testing. Geneva: World Health Organization; 2017 (https://iris.who.int/handle/10665/254621). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.28.json
  30. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization; 2018 (https://iris.who.int/handle/10665/273174). Licence: CC BY-NC-SA 3.0 IGO
    · extracted · link · source: references/10665-385385.sec-007.29.json
  31. elimination: guidelines. Geneva: World Health Organization; 2019 (https://iris.who.int/handle/10665/310912).
    · extracted · link · source: references/10665-385385.sec-007.30.json
  32. elimination: web annex 1: standard operating procedures (SOPs) for enhanced reporting of cases of acute hepatitis. Geneva: World Health Organization; 2019 (https://iris.who.int/handle/10665/280098). Licence: CC
    · extracted · link · source: references/10665-385385.sec-007.31.json
  33. elimination: web annex 2: template protocol for surveys to estimate the prevalence of biomarkers of infection with the hepatitis viruses. Geneva: World Health Organization; 2019 (https://iris.who.int/handle/10665/280099).
    · extracted · link · source: references/10665-385385.sec-007.32.json
  34. Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral prophylaxis in pregnancy. Geneva: World Health Organization; 2020 (https://iris.who.int/handle/10665/333391). Licence: CC BY-NC-SA 3.0
    · extracted · link · source: references/10665-385385.sec-007.33.json
  35. Recommendations and guidance on hepatitis C virus self-testing. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/342803). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.34.json
  36. Updated recommendations on treatment of adolescents and children with chronic HCV infection, and HCV simplified service delivery and diagnostics. Geneva: World Health Organization; 2022 (https://iris.who.int/handle/10665/363590). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.35.json
  37. Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations. Geneva: World Health Organization; 2022 (https://iris.who.int/handle/10665/360601). Licence: CC
    · extracted · link · source: references/10665-385385.sec-007.36.json · held: library/10665-360601
  38. Guidance for national strategic planning (NSP): health sector response to HIV, viral hepatitis and sexually transmitted infections. Geneva: World Health Organization; 2023 (https://iris.who.int/handle/10665/373523).
    · extracted · link · source: references/10665-385385.sec-007.37.json
  39. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Geneva: World Health Organization; 2024 (https://iris.who.int/handle/10665/376353). Licence: CC BY-NC-SA 3.0
    · extracted · link · source: references/10665-385385.sec-007.38.json
  40. Consolidated guidelines on person-centred viral hepatitis strategic information: using data to support country scale-up of hepatitis prevention, diagnosis and treatment services. Geneva: World Health Organization; 2024 (https://iris.who.int/handle/10665/376410). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.39.json
  41. Priorities in planning person-centred hepatitis B and C testing services: operational guide. Geneva: World Health Organization; 2024 (https://iris.who.int/handle/10665/379688). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.40.json
  42. World Health Organization & United Nations Children's Fund (UNICEF). Country guidance for planning triple elimination of mother-to-child transmission of HIV, syphilis and hepatitis B virus programmes. Geneva: World Health Organization; 2025 (https://iris.who.int/handle/10665/381914). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.41.json
  43. Consolidated guidance on hepatitis B and C prevention, testing, treatment, service delivery and monitoring: an implementation handbook for a public health approach. Geneva: World Health Organization; 2026 ( https://iris.who.int/handle/10665/384902). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.42.json
  44. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335-52 (https://doi.org/10.1016/j.jhep.2007.11.011).
    · extracted · doi:10.1016/j.jhep.2007.11.011 · source: references/10665-385385.sec-007.43.json
  45. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1 Suppl):S58-68 (https://doi.org/10.1016/j.jhep.2014.07.012).| 73
    · extracted · doi:10.1016/j.jhep.2014.07.012).| · source: references/10665-385385.sec-007.44.json
  46. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49(5 Suppl):S45-55 (https://doi.org/10.1002/hep.22898).
    · extracted · doi:10.1002/hep.22898 · source: references/10665-385385.sec-007.45.json
  47. Edmunds W, Medley G, Nokes D, Hall A, Whittle H. The influence of age on the development of the hepatitis B carrier state. Proceedings of the Royal Society of London Series B: Biological Sciences. 1993;253(1337):197-201 (https://doi.org/10.1098/rspb.1993.0102 ).
    · extracted · doi:10.1098/rspb.1993.0102 · source: references/10665-385385.sec-007.46.json
  48. Artenie A, Trickey A, Looker KJ, Stone J, Lim AG, Fraser H et al. Global, regional, and national estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a multi-stage analysis. Lancet Gastroenterol Hepatol. 2025;10(4):315-31 (https://doi.org/10.1016/s2468-1253(24)00442-4). PMICD:PMC12179389).
    · extracted · doi:10.1016/s2468-1253(24)00442-4 · source: references/10665-385385.sec-007.47.json
  49. Cousins S. Egypt's hepatitis success story. Lancet. 2024;403(10431):1011-2 (https://doi.org/10.1016/S0140-6736(24)00531-2).
    · extracted · doi:10.1016/S0140-6736(24)00531-2 · source: references/10665-385385.sec-007.48.json
  50. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000;355(9207):887-91 (https://doi.org/10.1016/s0140-6736(99)06527-7).
    · extracted · doi:10.1016/s0140-6736(99)06527-7 · source: references/10665-385385.sec-007.49.json
  51. Rao MR, Naficy AB, Darwish MA, Darwish NM, Schisterman E, Clemens JD et al. Further evidence for association of hepatitis C infection with parenteral schistosomiasis treatment in Egypt. BMC Infect Dis. 2002;2:29 (https://doi.org/10.1186/1471-2334-2-29). PMICD:PMC139974).
    · extracted · doi:10.1186/1471-2334-2-29 · source: references/10665-385385.sec-007.50.json
  52. Alaama AS, Jamil MS, Wilson N, Allegranzi B. Breaking barriers to hepatitis C elimination in the WHO Eastern Mediterranean Region. Lancet Gastroenterol Hepatol. 2025;10(10):874-6 (https://doi.org/10.1016/S2468-1253(25)00240-7).
    · extracted · doi:10.1016/S2468-1253(25)00240-7 · source: references/10665-385385.sec-007.51.json
  53. Global tuberculosis report 2025. Geneva: World Health Organization; 2025 (https://iris.who.int/handle/10665/383364). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.52.json
  54. Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C et al. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J Hepatol. 2020;73(3):523-32 (https://doi.org/10.1016/j.jhep.2020.04.008). PMICD:PMC7438974).
    · extracted · doi:10.1016/j.jhep.2020.04.008 · source: references/10665-385385.sec-007.53.json
  55. Polaris Observatory Collaborators. Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories. J Hepatol. 2024;80(2):232-42 (https://doi.org/10.1016/j.jhep.2023.10.043).
    · extracted · doi:10.1016/j.jhep.2023.10.043 · source: references/10665-385385.sec-007.54.json
  56. World Health Organization. Hepatitis B vaccines: WHO position paper - recommendations. Vaccine. 2010;28(3):589-90 (https://doi.org/10.1016/j.vaccine.2009.10.110).
    · extracted · doi:10.1016/j.vaccine.2009.10.110 · source: references/10665-385385.sec-007.55.json
  57. Hepatitis B vaccination policies, practices and challenges to achieving hepatitis elimination in the European Union and European Economic Area. Stockholm: European Centre for Disease Prevention and Control; 2025 (https://www.ecdc.europa.eu/en/publications-data/hepatitis-b-vaccination-policies-practices-and-challenges-achieving-hepatitis).
    · extracted · link · source: references/10665-385385.sec-007.56.json
  58. Chaudhary RK. Perinatal transmission of hepatitis B virus. Can Med Assoc J. 1983;128(6):664-6 (PMICD: PMC1875192, https://pubmed.ncbi.nlm.nih.gov/6825030/).
    · extracted · link · source: references/10665-385385.sec-007.57.json
  59. Keane E, Funk AL, Shimakawa Y. Systematic review with meta-analysis: the risk of mother-to-child transmission of hepatitis B virus infection in sub-Saharan Africa. Aliment Pharmacol Ther. 2016;44(10):1005-17 (https://doi.org/10.1111/apt.13795).
    · extracted · doi:10.1111/apt.13795 · source: references/10665-385385.sec-007.58.json
  60. Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol. 1977;105(2):94-8 (https://doi.org/10.1093/oxfordjournals.aje.a112370).
    · extracted · doi:10.1093/oxfordjournals.aje.a112370 · source: references/10665-385385.sec-007.59.json
  61. Okada K, Kamiyama I, Inomata M, Imai M, Miyakawa Y, Mayumi M. e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med. 1976;294(14):746-9 (https://doi.org/10.1056/NEJM197604012941402).
    · extracted · doi:10.1056/NEJM197604012941402 · source: references/10665-385385.sec-007.60.json
  62. Shimakawa Y, Bottomley C, Njie R, Mendy M. The association between maternal hepatitis B e antigen status, as a proxy for perinatal transmission, and the risk of hepatitis B e antigenaemia in Gambian children. BMC Public Health. 2014;14:532 (https://doi.org/10.1186/1471-2458-14-532). PMICD:PMC4066313).
    · extracted · doi:10.1186/1471-2458-14-532 · source: references/10665-385385.sec-007.61.json
  63. Brown RS, Jr., McMahon BJ, Lok ASF, Wong JB, Ahmed AT, Mouchli MA et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. Hepatology. 2016;63(1):319-33 (https://doi.org/10.1002/hep.28302).
    · extracted · doi:10.1002/hep.28302 · source: references/10665-385385.sec-007.62.json
  64. Machaira M, Papaevangelou V, Vouloumanou EK, Tansarli GS, Falagas ME. Hepatitis B vaccine alone or with hepatitis B immunoglobulin in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis. J Antimicrob Chemother. 2015;70(2):396-404 (https://doi.org/10.1093/jac/dku404).
    · extracted · doi:10.1093/jac/dku404 · source: references/10665-385385.sec-007.63.json
  65. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev. 2006(2):Cd004790 (https://doi.org/10.1002/14651858.CD004790.pub2).
    · extracted · doi:10.1002/14651858.CD004790.pub2 · source: references/10665-385385.sec-007.64.json
  66. Operational Data Portal: Bangladesh. [website]. UN Refugee Agency; (https://data.unhcr.org/en/country/bgd).
    · extracted · link · source: references/10665-385385.sec-007.65.json
  67. Samarasekera U. Hepatitis C epidemic among Rohingya refugees in Cox's Bazar: a public health emergency. The Lancet Gastroenterology & Hepatology. 2024;9(9):789 (https://doi.org/10.1016/S2468-1253(24)00230-9).
    · extracted · doi:10.1016/S2468-1253(24)00230-9 · source: references/10665-385385.sec-007.66.json
  68. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva: World Health Organization; 2014 (https://iris.who.int/handle/10665/111747). Licence: CC BY-NC-SA 3.0 IGO. 74 | Global hepatitis report 2026
    · extracted · link · source: references/10665-385385.sec-007.67.json
  69. Estes C, Abdel-Kareem M, Abdel-Razek W, Abdel-Sameea E, Abuzeid M, Gomaa A et al. Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies. Aliment Pharmacol Ther. 2015;42(6):696-706 (https://doi.org/10.1111/apt.13316). PMICD:PMC5034818).
    · extracted · doi:10.1111/apt.13316 · source: references/10665-385385.sec-007.68.json
  70. Screening donated blood for transfusion‑transmissible infections: recommendations. Geneva: World Health Organization; 2009 (https://iris.who.int/handle/10665/44202). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.69.json
  71. Action framework to advance universal access to safe, effective and quality-assured blood products 2020–2023. World Health Organization; 2020 (https://iris.who.int/handle/10665/331002). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.70.json
  72. Global status report on blood safety and availability 2021. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/356165). Licence: CC BY-NCSA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.71.json
  73. Candotti D, Boizeau L, Laperche S. Occult hepatitis B infection and transfusion-transmission risk. Transfus Clin Biol. 2017;24(3):189-95 (https://doi.org/10.1016/j.tracli.2017.06.014).
    · extracted · doi:10.1016/j.tracli.2017.06.014 · source: references/10665-385385.sec-007.72.json
  74. Busch MP, Bloch EM, Kleinman S. Prevention of transfusion-transmitted infections. Blood. 2019;133(17):1854-64 (https://doi.org/10.1182/blood-2018-11-833996).
    · extracted · doi:10.1182/blood-2018-11-833996 · source: references/10665-385385.sec-007.73.json
  75. Rapiti E, Dhingra N, Hutin Y, Lloyd S. The global burden of HBV and HCV infection attributable to unsafe blood transfusions (poster). In: 11th International Symposium on Viral Hepatitis and Liver Disease. Sydney, Australia; 2003.
    · extracted · source: references/10665-385385.sec-007.74.json
  76. Ahmed Kiani R, Anwar M, Waheed U, Asad MJ, Abbasi S, Abbas Zaheer H. Epidemiology of Transfusion Transmitted Infection among Patients with β‐Thalassaemia Major in Pakistan. Journal of blood transfusion. 2016;2016(1):8135649 (https://doi.org/10.1155/2016/8135649).
    · extracted · doi:10.1155/2016/8135649 · source: references/10665-385385.sec-007.75.json
  77. Tagny CT, Owusu‐Ofori S, Mbanya D, Deneys V. The blood donor in sub‐Saharan Africa: a review. Transfus Med. 2010;20(1):1-10 (https://doi.org/10.1111/j.1365-3148.2009.00958.x).
    · extracted · doi:10.1111/j.1365-3148.2009.00958.x · source: references/10665-385385.sec-007.76.json
  78. World Bank country and lending groups [website]. World Bank; 2026 (https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups).
    · extracted · link · source: references/10665-385385.sec-007.77.json
  79. Make smart injection choices: safe injection practices (pamphlet). Geneva: World Health Organization; 2017 (https://cdn.who.int/media/docs/default-source/integrated-health-services-(ihs)/infection-prevention-and-control/injection-safety/advocacy/is_healthcareproviders_leaflet.pdf). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.78.json
  80. WHO guideline on the use of safety-engineered syringes for intramuscular, intradermal and subcutaneous injections in health care settings. Geneva: World Health Organization; 2016 (https://iris.who.int/handle/10665/250144). Licence: 9789241549820.
    · extracted · link · source: references/10665-385385.sec-007.79.json
  81. Hayashi T, Hutin YJ-F, Bulterys M, Altaf A, Allegranzi B. Injection practices in 2011–2015: a review using data from the demographic and health surveys (DHS). BMC health services research. 2019;19(1):600 (https://doi.org/10.1186/s12913-019-4366-9).
    · extracted · doi:10.1186/s12913-019-4366-9 · source: references/10665-385385.sec-007.80.json
  82. Global action plan and monitoring framework on infection prevention and control (IPC), 2024–2030. Geneva: World Health Organization; 2024 (https://www.who.int/teams/integrated-health-services/infection-prevention-control/draft-global-action-plan-and-monitoring-framework-on-ipc#cms). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.81.json
  83. Global report on infection prevention and control 2024. Geneva: World Health Organization; 2024 (https://iris.who.int/handle/10665/379632). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.82.json
  84. The global state of harm reduction 2024 (9th edition). London: Harm Reduction International; 2024 (https://hri.global/flagship-research/the-global-state-of-harm-reduction/the-global-state-of-harm-reduction-2024/).
    · extracted · link · source: references/10665-385385.sec-007.83.json
  85. Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders. Geneva: World Health Organization; 2024 (https://iris.who.int/handle/10665/375767.). Licence: CC
    · extracted · link · source: references/10665-385385.sec-007.84.json
  86. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. World Health Organization. Geneva: World Health Organization; 2009 (https://iris.who.int/handle/10665/43948). Licence: CC
    · extracted · link · source: references/10665-385385.sec-007.85.json
  87. World Drug Report 2025 [website]. United Nations Office on Drugs and Crime; 2025 (https://www.unodc.org/unodc/en/data-and-analysis/world-drug-report-2025.html).
    · extracted · link · source: references/10665-385385.sec-007.86.json
  88. Global status report on alcohol and health and treatment of substance use disorders. Geneva: World Health Organization; 2024 (https://iris.who.int/handle/10665/377960). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.87.json
  89. Needle and syringe programmes for people who inject drugs: operational guide. Geneva: World Health Organization; 2025 (https://iris.who.int/handle/10665/384810). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-007.88.json
  90. Colledge-Frisby S, Ottaviano S, Webb P, Grebely J, Wheeler A, Cunningham EB et al. Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review. The Lancet Global Health. 2023;11(5):e673-e83 (https://doi.org/10.1016/S2214-109X(23)00058-X).
    · extracted · doi:10.1016/S2214-109X(23)00058-X · source: references/10665-385385.sec-007.89.json
  91. Global AIDS monitoring, 2024 [website]. UNAIDS; 2024 (https://www.unaids.org/en/global-aids-monitoring).
    · extracted · link · source: references/10665-385385.sec-007.90.json
  92. Unitaid investments in hepatitis C – portfolio evaluation and end‑of‑grant evaluations of the FIND HEAD‑Start and Coalition PLUS grants. Geneva: Unitaid; 2021 (https://unitaid.org/uploads/Final_Report_HCVEvaluation_CEPA-1-1.pdf).| 75
    · extracted · link · source: references/10665-385385.sec-007.91.json
  93. Unitaid landscape report: eliminating vertical transmission of HIV, hepatitis B, syphilis, and Chagas disease [website]. Unitaid; 2026 (https://unitaid.org/project/eliminating-vertical-transmission-of-hiv-hepatitis-b-syphilis-and-chagas-disease/).
    · extracted · link · source: references/10665-385385.sec-007.92.json
  94. Painel de Monitoramento de Hepatites B e C [website]. Ministério da Saúde Secretaria de Vigilância em Saúde e Ambiente, Departamento de HIV Aids, Tuberculose Hepatites Virais e IST; (https://www.gov.br/aids/pt-br/indicadores-epidemiologicos/painel-de-monitoramento-de-hepatites-b-e-c).
    · extracted · link · source: references/10665-385385.sec-007.93.json
  95. Nota Técnica nº 11/2025 – CGIST/DATHI/SVSA/MS. Brasília, Brazil: Ministério da Saúde Secretaria de Vigilância em Saúde e Ambiente, Departamento de HIV Aids, Tuberculose Hepatites Virais e IST; 2025 (https://www.gov.br/aids/pt-br/central-de-conteudo/notas-tecnicas/2025/nota-tecnica_no-11_2025_cgist_dathi_svsa_ms.pdf).
    · extracted · link · source: references/10665-385385.sec-007.94.json
  96. Guia para a Eliminação das Hepatites Virais no Brasil. Brasília, Brazil: Ministério da Saúde, Secretaria de Vigilância em Saúde e Ambiente, Departamento de HIV, Aids, Tuberculose, Hepatites Virais e IST; 2025 (https://bvsms.saude.gov.br/bvs/publicacoes/guia_eliminacao_hepatites_virais_Brasil.pdf).
    · extracted · link · source: references/10665-385385.sec-007.95.json
  97. Boletim Epidemiológico – Hepatites Virais 2025. Brasília, Brazil: Ministério da Saúde, Secretaria de Vigilância em Saúde e Ambiente, Departamento de HIV, Aids, Tuberculose, Hepatites Virais e IST; 2025 (https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/boletins/epidemiologicos/especiais/2025/boletim-epidemiologico-de-hepatites-virais.pdf).
    · extracted · link · source: references/10665-385385.sec-007.96.json
  98. Gomaa A, Gomaa M, Allam N, Waked I. Hepatitis C elimination in Egypt: story of success. Pathogens. 2024;13(8):681 (https://doi.org/10.3390/pathogens13080681).
    · extracted · doi:10.3390/pathogens13080681 · source: references/10665-385385.sec-007.97.json
  99. Ezzat S, Gamkrelidze I, Osman A, Gomaa A, Roushdy A, Esmat G et al. Impacts of the Egyptian national screening and treatment programme for viral hepatitis C: a cost-effectiveness model. Liver Int. 2023;43(7):1417-26 (https://doi.org/10.1111/liv.15584).
    · extracted · doi:10.1111/liv.15584 · source: references/10665-385385.sec-007.98.json
  100. Egypt’s viral hepatitis program – burden and response: an economic analysis. Washington D.C., U.S.A.: World Bank; 2017 (https://documents1.worldbank.org/curated/en/972381517328583384/pdf/123066-WP-PUBLIC-P157533-Burden-and-response-An-Economic-Analysis.pdf).
    · extracted · link · source: references/10665-385385.sec-007.99.json
  101. Salomon I, Olivier S, Egide N. Advancing hepatitis C elimination in Africa: insights from Egypt. Hepatic Med. 2024:37-44 (https://doi.org/10.2147/HMER.S470344).
    · extracted · doi:10.2147/HMER.S470344 · source: references/10665-385385.sec-007.100.json
  102. Qureshi H, Mahmood H, Saleem S, Aabroo A. Prime Minister’s hepatitis C elimination program in Pakistan. In: Elimination of Viral Hepatitis B and C–Global Initiatives, National Programs, and Scientific Advances: IntechOpen; 2025: (https://doi.org/10.5772/intechopen.115658).
    · extracted · doi:10.5772/intechopen.115658 · source: references/10665-385385.sec-007.101.json
  103. Lim AG, Scott N, Walker JG, Hamid S, Hellard M, Vickerman P. Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis. PLoS medicine. 2021;18(10):e1003818 (https://doi.org/10.1371/journal.pmed.1003818).
    · extracted · doi:10.1371/journal.pmed.1003818 · source: references/10665-385385.sec-007.102.json
  104. Selden O, Rusingiza E, Balkrishnan R. Overview, infrastructural challenges, barriers to access, and progress for Rwanda’s healthcare system: a review. Integrative Journal of Medical Sciences. 2025;12 (https://doi.org/10.15342/ijms.2025.745).
    · extracted · doi:10.15342/ijms.2025.745 · source: references/10665-385385.sec-007.103.json
  105. Zhong H, Aaron A, Hiebert L, Serumondo J, Zhuo Y, Adee M et al. Hepatitis C elimination in Rwanda: progress, feasibility, and economic evaluation. Value Health. 2024;27(7):918-25 (https://doi.org/10.1016/j.jval.2024.03.005).
    · extracted · doi:10.1016/j.jval.2024.03.005 · source: references/10665-385385.sec-007.104.json
  106. Hepatitis C elimination: Rwanda on the last mile [website]. Ministry of Health Rwanda; 2022 (https://www.moh.gov.rw/news-detail/hepatitis-c-elimination-rwanda-on-the-last-mile).
    · extracted · link · source: references/10665-385385.sec-007.105.json
  107. The national digital health strategic plan, 2018–2023 [website]. Ministry of Health Rwanda; 2018 (https://extranet.who.int/countryplanningcycles/sites/default/files/public_file_rep/RWA_Rwanda_Digital-Health-Strategy_2018-2023.Pdf).
    · extracted · link · source: references/10665-385385.sec-007.106.json
  108. Kanokudom S, Nilyanimit P, Puenpa J, Suntronwong N, Le DHH, Wongsrisang L et al. A comparative national survey on the gradual decline of hepatitis C virus prevalence in Thailand, 2004, 2014, and 2024. Sci Rep. 2025;15(1):19794 (https://doi.org/10.1038/s41598-025-04578-0).
    · extracted · doi:10.1038/s41598-025-04578-0 · source: references/10665-385385.sec-007.107.json
  109. Tangcharoensathien V, Witthayapipopsakul W, Panichkriangkrai W, Patcharanarumol W, Mills A. Health systems development in Thailand: a solid platform for successful implementation of universal health coverage. Lancet. 2018;391(10126):1205-23 (https://doi.org/10.1016/S0140-6736(18)30198-3).
    · extracted · doi:10.1016/S0140-6736(18)30198-3 · source: references/10665-385385.sec-007.108.json
  110. Degenhardt L, Webb P, Colledge-Frisby S, Ireland J, Wheeler A, Ottaviano S et al. Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review. Lancet Glob Health. 2023;11(5):e659-e72 (https://doi.org/10.1016/S2214-109X(23)00057-8. PMICD:PMC12580156). The following references were accessed on 23 April 2026: 7, 8,12, 18, 56, 77, 81, 83, 86, 90–96, 105 and 106.
    · extracted · doi:10.1016/S2214-109X(23)00057-8 · source: references/10665-385385.sec-007.109.json
  111. Global hepatitis report 2017. Geneva: World Health Organization; 2017 (https://iris.who.int/handle/10665/255016). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-008.1.json
  112. Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva: World Health Organization; 2024 (https://iris.who.int/handle/10665/376461). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-008.2.json
  113. Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. Geneva: World Health Organization; 2016 (https://iris.who.int/handle/10665/246177).
    · extracted · link · source: references/10665-385385.sec-008.3.json
  114. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022–2030. Geneva: World Health Organization; 2022 (https://iris.who.int/handle/10665/360348).Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-008.4.json
  115. Viral hepatitis country profiles [website]. World Health Organization; 2025 (https://data.who.int/dashboards/hepatitis/epidemiology).
    · extracted · link · source: references/10665-385385.sec-008.5.json
  116. Guidance for country validation of viral hepatitis elimination and path to elimination: technical report. Geneva: World Health Organization; 2023 (https://iris.who.int/handle/10665/373186). Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-008.6.json
  117. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Geneva: World Health Organization; 2024 (https://iris.who.int/handle/10665/376353). Licence: CC BY-NC-SA 3.0
    · extracted · link · source: references/10665-385385.sec-008.7.json
  118. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022–2030. Geneva: World Health Organization; 2022 (https://iris.who.int/handle/10665/360348).Licence: CC BY-NC-SA 3.0 IGO.
    · extracted · link · source: references/10665-385385.sec-009.1.json
  119. Global reporting on HIV, hepatitis, and STIs [website]. World Health Organization; 2026 (https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/strategies/global-health-sector-strategies/global-reporting-on-hiv-hepatitis-and-stis).
    · extracted · link · source: references/10665-385385.sec-009.2.json
  120. Resolution WHA63.18. Viral hepatitis. In: Sixty-third World Health Assembly, Geneva, 17–21 May 2010. Resolutions and decisions, annexes. Geneva: World Health Organization; 2010 (http://apps.who.int/gb/ebwha/pdf_files/WHA63-REC1/WHA63_REC1-en.pdf).
    · extracted · link · source: references/10665-385385.sec-010.1.json
  121. Resolution WHA67.6. Hepatitis. In: Sixty-seventh World Health Assembly, Geneva, 19–24 May 2014. Resolutions and decisions, annexes. Geneva: World Health Organization; 2014 (http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R6-en.pdf).Box A3.2. The second World Health Assembly resolution on viral hepatitis in 2014 (WHA67.6): summary of Member State commitments and requests to WHO (2) f National strategies. Develop and implement coordinated multisectoral strategies for prevention, diagnosis and treatment, based on local epidemiology. f Health promotion and immunization. Strengthen health promotion and prevention, and enhance immunization strategies, including for hepatitis A, and for hepatitis B through a timely birth dose.
    · extracted · link · source: references/10665-385385.sec-010.2.json